Urodynamix Announces Grant of Stock Options

Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced today that it has
issued 2,000,000 stock options to employees of the Company. The stock options
are being offered in conformance with TSX Venture Exchange regulations as
incentive compensation and have a term of five years and an exercise price of
$0.11 per share.


Following the issuance of these options, Urodynamix has outstanding 107,227,893
common shares and 9,213,500 incentive stock options. The company's Stock Option
Plan allows the Board to issue the equivalent of up to 10% of the issued and
outstanding share capital of the company on a rolling basis and was approved at
the company's last Annual General Meeting held on June 9, 2008.


About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Juil 2024 à Août 2024